InMed Historical Balance Sheet
INM Stock | USD 5.26 0.11 2.14% |
Trend analysis of InMed Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 9.7 M or Property Plant And Equipment Net of 1.3 M provides information on InMed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of InMed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using InMed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining InMed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InMed Pharmaceuticals is a good buy for the upcoming year.
InMed Pharmaceuticals Inventory |
|
InMed |
About InMed Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of InMed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. InMed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of InMed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which InMed currently owns. An asset can also be divided into two categories, current and non-current.
InMed Pharmaceuticals Balance Sheet Chart
Add Fundamental
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most accounts from InMed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of December 2024, Short Term Investments is likely to grow to about 45.2 M, though Net Debt is likely to grow to (5.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 3.3M | 2.0M | 2.0M | 1.1M | Total Assets | 12.8M | 14.1M | 11.8M | 12.4M |
InMed Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
InMed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
InMed Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.5M | 9.8M | 12.8M | 14.1M | 11.8M | 12.4M | |
Total Current Liabilities | 1.7M | 2.2M | 3.3M | 2.0M | 2.0M | 1.1M | |
Total Stockholder Equity | 5.6M | 7.4M | 9.1M | 12.1M | 9.2M | 9.7M | |
Property Plant And Equipment Net | 402.6K | 326.6K | 904.3K | 723.4K | 1.2M | 1.3M | |
Net Debt | (5.5M) | (7.1M) | (5.4M) | (8.5M) | (5.6M) | (5.3M) | |
Retained Earnings | (56.0M) | (74.9M) | (93.5M) | (101.4M) | (109.1M) | (103.6M) | |
Accounts Payable | 959.2K | 775.1K | 1.2M | 544.2K | 626.2K | 615.9K | |
Cash | 5.8M | 7.4M | 6.2M | 8.9M | 6.6M | 3.4M | |
Non Current Assets Total | 1.2M | 1.4M | 3.2M | 2.8M | 3.1M | 3.3M | |
Cash And Short Term Investments | 5.8M | 7.4M | 6.2M | 8.9M | 6.6M | 3.9M | |
Net Receivables | 45.2K | 11.9K | 88.0K | 260.4K | 352.8K | 370.5K | |
Common Stock Shares Outstanding | 208.8K | 270K | 560.8K | 2.4M | 7.6M | 8.0M | |
Short Term Investments | 42.3K | 46.5K | 44.8K | 44.4M | 43.1M | 45.2M | |
Liabilities And Stockholders Equity | 7.5M | 9.8M | 12.8M | 14.1M | 11.8M | 12.4M | |
Non Current Liabilities Total | 247.5K | 189.3K | 389.5K | 16.0K | 644.9K | 677.1K | |
Inventory | (919.56) | (955.8M) | 2.5M | 1.6M | 1.2M | 1.3M | |
Other Current Assets | 418.9K | 956.8K | 842.0K | (8.9B) | 477.7K | 501.6K | |
Other Stockholder Equity | (59.5M) | 21.5M | 31.7M | 35.7M | 35.4M | 37.1M | |
Total Liab | 1.9M | 2.4M | 3.7M | 2.0M | 2.6M | 2.7M | |
Total Current Assets | 6.3M | 8.4M | 9.6M | 11.3M | 8.7M | 9.1M | |
Accumulated Other Comprehensive Income | 59.6M | 63.4M | 70.8M | 128.6K | 147.9K | 140.5K | |
Intangible Assets | 799.3K | 1.1M | 2.1M | 1.9M | 1.8M | 1.9M | |
Common Stock | 50.2M | 60.6M | 70.7M | 77.6M | 82.8M | 53.5M | |
Net Tangible Assets | 6.5M | 6.3M | 7.0M | 10.1M | 9.1M | 9.1M | |
Net Invested Capital | 5.6M | 7.4M | 9.1M | 12.1M | 9.2M | 8.4M | |
Net Working Capital | 4.6M | 6.2M | 6.3M | 9.3M | 6.7M | 7.1M | |
Property Plant Equipment | 549.9K | 326.6K | 904.3K | 723.4K | 831.9K | 873.5K | |
Capital Stock | 50.2M | 60.6M | 70.7M | 77.6M | 82.8M | 72.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.